Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials
Eron, Joseph J, Prof, Cooper, David A, Prof, Steigbigel, Roy T, Prof, Clotet, Bonaventura, MD, Gatell, Jose M, Prof, Kumar, Princy N, Prof, Rockstroh, Jurgen K, Prof, Schechter, Mauro, Prof, Markowitz, Martin, Prof, Yeni, Patrick, MD, Loutfy, Mona R, MD, Lazzarin, Adriano, Prof, Lennox, Jeffrey L, Prof, Strohmaier, Kim M, BS, Wan, Hong, MS, Barnard, Richard JO, PhD, Nguyen, Bach-Yen T, MD, Teppler, Hedy, MD
Published in The Lancet infectious diseases (01.07.2013)
Published in The Lancet infectious diseases (01.07.2013)
Get full text
Journal Article
Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis
Boyd, Mark A, Moore, Cecilia L, Molina, Jean-Michel, Wood, Robin, Madero, Juan S, Wolff, Marcelo, Ruxrungtham, Kiat, Losso, Marcelo, Renjifo, Boris, Teppler, Hedy, Kelleher, Anthony D, Amin, Janaki, Emery, Sean, Cooper, David A
Published in The lancet HIV (01.02.2015)
Published in The lancet HIV (01.02.2015)
Get more information
Journal Article